Diagnostic information from PSMA PET/CT can play an important role in directing the course of therapy; however, early efforts to use PSMA-based radioligand therapy in ccRCC have been limited by rapid tracer washout from the sites of disease. This evidence concerns the gene FOLH1 and nonpapillary renal cell carcinoma.